TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2021 to be made to analysts is enclosed for your records. TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30th September, 2021 to be made to analysts is enclosed for your records. Q2FY22 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Highlights Revenue at Rs. 2,137 crores up by 6% Gross margins: 72.2%; EBITDA margins: 33.2% EBITDA at Rs. 711 crores was up by 11%. Profit before tax at Rs. 472 crores was up by 23%. Net profit after tax at Rs. 316 crores was up 2% India: India revenues at Rs 1,087 crores grew by 13% Underlying growth adjusted for dispatch related delays last year is at 16% As per secondary market data (AIOCD), Torrent’s Q2 FY22 growth was 19% versus IPM growth of 15% Torrent has outperformed the market in all its key therapies during the quarter. MR productivity for the quarter was Rs 9.9 lakhs with MR strength of 3,600 For H1 FY22, revenues were Rs 2,180 crores, up by 15%. United States: US revenues at Rs 284 crores, were down by 13%. Constant currency sales were $35 million. Sales were lower due to price erosion in the base business and lack of new approvals pending re-inspection of facilities. As on September 30, 2021, 53 ANDAs were pending approval with USFDA and 7 tentative approvals were received. 1 ANDA was approved during the quarter. For H1 FY22, revenues were Rs 550 crores, down by 21% (Constant currency sales: $71 million). Brazil: Brazil revenues at Rs 156 crores, were up by 21% Constant currency sales at R$ 109 million. Brazil BGx market growth is at 10% during the quarter. Growth was driven by momentum in the large brands combined with the strong launch of two new products. For H1 FY22, revenues were Rs 309 crores, up by 15% (Constant currency sales: R$ 218 million, up by 16%). Germany: Germany revenues at Rs 251 crores were down by 4% Constant currency sales were Euro 29 million. Growth during the quarter was mainly impacted due to covid induced supply delays and inventory normalization led by customer consolidation at market place. Secondary sales trend was in-line with market growth. For H1 FY22, revenues were Rs 510 crores, up by 1% (Constant currency sales: Euro 58 million). Result PDF Torrent Pharmaceuticals Ltd - 500420 - Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (''Listing Regulations'')
Outcome of Board Meeting dated 26-Oct-2021 Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
In furtherance to our letter dated 11-Oct-21 on the captioned subject, we would like to inform that the teleconference with Investors / Analyst has been rescheduled to 06:30 P.M. from 06:00 P.M. on 26th October, 2021 to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2021. The Dial-in details shall remain same as mentioned in our letter dated 11-Oct-21. TORRENT PHARMACEUTICALS LTD. - 500420 - Shareholding for the Period Ended September 30, 2021
Torrent Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 26th October, 2021 at 06:00 P.M. to discuss the financial performance of the Company for the quarter and half year ended 30th September, 2021. Torrent Pharmaceuticals Ltd - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2021 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Tuesday, 26-Oct-21, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-21. Torrent Pharmaceuticals Ltd - 500420 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Mahesh AgrawalDesignation :- Company Secretary and Compliance Officer